Bromocriptine in polycystic ovarian disease: a controlled clinical trial.

Abstract

Bromocriptine and placebo were given to a group of 20 polycystic ovarian disease patients on a double-blind, cross-over basis. Patients were studied for three cycles: a baseline cycle without any medication, a placebo-treated cycle, and a bromocriptine-treated cycle with multiple plasma samples taken during the different phases of the menstrual cycle. The clinical response to bromocriptine was compared with that of a placebo for the following hormones: prolactin (PRL), luteinizing hormone (LH)/follicle-stimulating hormone (FSH) ratio, testosterone, androstenedione, estradiol-17 beta (E2), estrone (E1), and progesterone. Patients were divided into two subgroups: hyperprolactinemic (basal PRL greater than 20 ng/mL) and normoprolactinemic (basal PRL less than 20 ng/mL), and the response of both subgroups to bromocriptine was compared. Prolactin, LH/FSH ratio, testosterone, and E1 showed a significant drop with bromocriptine, whereas E2 significantly increased. Two out of nine amenorrheic polycystic ovarian disease patients menstruated during bromocriptine treatment, and three patients showed evidence of ovulation.

• Authors: G H el Tabbakh, I A Loutfi, I Azab, H A Rahman, A L Southren, F A Aleem
• Journal: Obstetrics and gynecology (Obstet Gynecol) Vol. 71 Issue 3 Pt 1 Pg. 301-6 (Mar 1988) ISSN: 0029-7844 [Print] United States
• PMID: 3279350 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Gonadal Steroid Hormones
• Bromocriptine

Topics

• Adolescent
• Adult
• Amenorrhea (complications, physiopathology)
• Bromocriptine (adverse effects, therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Gonadal Steroid Hormones (blood)
• Humans
• Menstruation
• Ovulation
• Polycystic Ovary Syndrome (blood, complications, drug therapy)